2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10572S
    Efavirenz-d5 1132642-95-5 98%
    Efavirenz-d5 (DMP 266-d5) is the deuterium labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture. Efavirenz-d5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Efavirenz-d5
  • HY-10574R
    Rilpivirine (Standard) 500287-72-9 98%
    Rilpivirine (Standard) is the analytical standard of Rilpivirine. This product is intended for research and analytical applications. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV.
    Rilpivirine (Standard)
  • HY-105751
    Kalafungin 11048-15-0 98%
    Kalafungin is an antibiotic, antimicrobial agent and a β-lactamase inhibitor from marine Streptomyces, with IC50 of 225.37 μM. Kalafungin destroys cell membranes. Kalafungin shows inhibitory activities against a variety of pathogenic fungi, yeasts, protozoa, gram-positive bacteria (such as S. aureus ATCC 33591 and S. aureus ATCC 23591), and, to a lesser extent, gram-negative bacteria.
    Kalafungin
  • HY-10581B
    Gatifloxacin mesylate 316819-28-0 98%
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin mesylate
  • HY-10581R
    Gatifloxacin (Standard) 112811-59-3 98%
    Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml). Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin (Standard)
  • HY-105832
    Fenbenicillin potassium 1177-30-6 98%
    Fenbenicillin (Phenbenicillin) potassium is semi-synthetic penicillin with antibacterial effecst.
    Fenbenicillin potassium
  • HY-106026
    YM 133 103360-00-5 98%
    YM 133 (IMC-XV) is a semisynthetic macrolide antibiotic with potent bactericidal activity. YM 133 shows activity against Erythromycin (HY-B0220)-, Josamycin (HY-B1920)-, and rokitamycin-resistant (MIC ≥ 100 μg/mL) strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp. YM 133 exhibits excellent activity against macrolide-resistant strains and against anaerobes. YM 133 can be used for antibacterial research.
    YM 133
  • HY-106095
    DQ 2556 102253-70-3 98%
    DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins.
    DQ 2556
  • HY-106119
    Camonagrel 105920-77-2 98%
    Camonagrel is a compound that has inhibitory effects on Prostaglandin E2. Camonagrel is a potent thromboxane synthase inhibitor.
    Camonagrel
  • HY-106247
    AG-1859 478410-84-3 98%
    AG-1859 is a viral protease inhibitor. AG-1859 can be used in the research of viral infection.
    AG-1859
  • HY-106291
    Cefclidin 105239-91-6 98%
    Cefclidin (Cefclidine) belongs to the cephalomycin-type compound.
    Cefclidin
  • HY-106304
    ME-1228 115369-52-3 98%
    ME-1228 is an antibacterial agent and sulfur-containing analogue of OCP 9-176. ME 1228 is generally twofold more active than OCP 9-176 against Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Providencia stuartii, Proteus vulgaris, and Serratia marcescens. ME-1228 has antibacterial activity against E. coli UB 1005, P. aeruginosa K779K, and P. aeruginosa E4, with MICs of 0.25, 0.25, and 1 μg/mL, respectively.
    ME-1228
  • HY-106312
    Viroxime 63198-97-0 98%
    Viroxime is an antiviral agent.
    Viroxime
  • HY-106322
    IO-21 114833-91-9 98%
    IO-21 (Compound 3) is a candidate cytoprotective agent. IO-21 exhibits a marked cytoprotective effect. IO-21 shows a potent inhibitory activity against HCl•ethanol-induced lesions. IO-21 shows a MIC of 50 μg/mL against Helicobacter pylori 7795. IO-21 can be used in the research of gastric mucosal ulcers.
    IO-21
  • HY-106333
    Irtemazole 129369-64-8 98%
    Irtemazole is an orally active antifungal agent. Irtemazole possesses uricosuric effect. Irtemazole is used in the research for blastomycosis, histoplasmosis, and aspergillosis.
    Irtemazole
  • HY-106350
    Cefpimizole 84880-03-5 98%
    Cefpimizole (U-63196E) is a broad-spectrum cephalosporin antibiotic. Cefpimizole inhibits many Ampicillin (HY-B0522)-resistant bacteria, and is active against gram-negative species. Cefpimizole augments phagocytosis of macrophages and neutrophils.
    Cefpimizole
  • HY-106352
    BMS 605339 630417-82-2 98%
    BMS 605339 is a linear tetra-peptide α-ketoamide inhibitor of HCV NS3 protease. BMS 605339 can be used in research related to hepatitis C (HCV infection).
    BMS 605339
  • HY-106472
    Tioxaprofen 40198-53-6 98%
    Tioxaprofen is a new anti-mycotic drug against Trichophyton mentagrophytes and T. rubrum, and is a potent uncoupling agent of mitochondrial respiration.
    Tioxaprofen
  • HY-106515
    Tebuquine 74129-03-6 98%
    Tebuquine (WR228258), a 4-aminoquinoline, is a potent antimalarial agent. Tebuquine is active against the Chloroquine (HY-17589A) sensitive HB3 strain and the Chloroquine resistant K1 strain of Plasmodium falciparum with IC50s of 0.9 nM and 20.8 nM, respectively.
    Tebuquine
  • HY-106546
    Tolciclate 50838-36-3 98%
    Tolciclate (KC 9147) is an antifungal agent with in vitro inhibitory activity against dermatophytes, effective at concentrations of 0.01-0.1 μg/mL. Tolciclate is colorless and soluble in well-tolerated excipients, and it is more lipophilic than Tolnaftate (HY-B0370). Tolciclate can be used in research related to antifungal infections.
    Tolciclate
Cat. No. Product Name / Synonyms Application Reactivity